Chiltern Acquires Ockham - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
Chiltern Acquires Ockham

Source: Applied Clinical Trials

Chiltern and Ockham, two full-service contract research organizations (CROs), announce that Chiltern has acquired 100% of Ockham and that the companies will merge their operations.

The combined company will be called Chiltern. Ockham’s management team will join the management of the enlarged group. Chiltern’s CEO Jim Esinhart, PhD will be CEO of the Chiltern Group, with Ockham’s CEO, James V. Baker, becoming Chief Development Officer. Nick Thornton will remain as Chairman.

The merged entity combines service offerings in three areas: oncology; services and FSP/Sourcing

Read the full release here.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
86%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
7%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here